ADAR1 Capital Management LLC Acquires New Holdings in Agios Pharmaceuticals, Inc. $AGIO

Key Points

• ADAR1 Capital Management LLC acquired 27,900 shares of Agios Pharmaceuticals valued at approximately $817,000 in the first quarter.
• Agios Pharmaceuticals reported a loss of $1.93 per share for the last quarter, missing expectations, but generated $12.50 million in revenue, surpassing analyst forecasts.
• Analysts have mixed reviews for AGIO, with ratings ranging from "buy" to "sell." The stock has a consensus target price of $56.33.

ADAR1 Capital Management LLC purchased a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the first quarter, according to its most recent filing with the SEC. The fund purchased 27,900 shares of the biopharmaceutical company's stock, valued at approximately $817,000.

Several other large investors have also recently added to or reduced their stakes in the company. Jefferies Financial Group Inc. acquired a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth $49,290,000. Palo Alto Investors LP acquired a new position in shares of Agios Pharmaceuticals in the 1st quarter valued at about $8,104,000. Paradigm Biocapital Advisors LP bought a new stake in shares of Agios Pharmaceuticals during the 4th quarter valued at about $9,084,000. Deutsche Bank AG raised its stake in Agios Pharmaceuticals by 39.7% during the fourth quarter. Deutsche Bank AG now owns 935,252 shares of the biopharmaceutical company's stock worth $30,732,000 after acquiring an additional 265,637 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Agios Pharmaceuticals by 207.6% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 386,523 shares of the biopharmaceutical company's stock worth $11,325,000 after acquiring an additional 260,845 shares during the last quarter.

Agios Pharmaceuticals Trading Down 0.3%

AGIO traded down $0.12 during trading hours on Friday, hitting $36.01. The company's stock had a trading volume of 1,481,598 shares, compared to its average volume of 661,170. The company has a 50-day simple moving average of $37.58 and a 200 day simple moving average of $33.20. Agios Pharmaceuticals, Inc. has a fifty-two week low of $23.42 and a fifty-two week high of $62.58. The firm has a market capitalization of $2.09 billion, a PE ratio of 3.27 and a beta of 0.87.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.74) by ($0.19). Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%.The company had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.46 million. Research analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. HC Wainwright restated a "buy" rating and issued a $56.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday. Bank of America reduced their price objective on Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd. Wall Street Zen downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. Finally, Scotiabank cut their target price on Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating on the stock in a research note on Monday, July 28th. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $56.00.

Insider Buying and Selling

In other news, insider Sarah Gheuens sold 11,914 shares of the firm's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $37.99, for a total transaction of $452,612.86. Following the completion of the sale, the insider directly owned 61,271 shares of the company's stock, valued at $2,327,685.29. This trade represents a 16.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Tsveta Milanova sold 2,770 shares of the business's stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total value of $92,905.80. Following the completion of the sale, the insider directly owned 26,122 shares of the company's stock, valued at approximately $876,131.88. The trade was a 9.59% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 57,448 shares of company stock valued at $2,026,141. 4.30% of the stock is currently owned by company insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.